Zanubrutinib
- CAS No.
- 1691249-45-2
- Chemical Name:
- Zanubrutinib
- Synonyms
- Zebutinib;anubrutinib;Zanubrutinib;Zanmubrutinib;Zanubtutinib AP;Zanubrutinib API;The BTK inhibitor;BGB-3111(Zanubrutinib);Zanubrutinib (BGB-3111);Zanubrutinib API & all impurites
- CBNumber:
- CB93361383
- Molecular Formula:
- C27H29N5O3
- Molecular Weight:
- 471.55
- MDL Number:
- MFCD31567461
- MOL File:
- 1691249-45-2.mol
| Boiling point | 713.4±60.0 °C(Predicted) |
|---|---|
| Density | 1.33±0.1 g/cm3(Predicted) |
| storage temp. | Store at -20°C |
| solubility |
DMSO:99.67(Max Conc. mg/mL);211.36(Max Conc. mM) DMF:10.0(Max Conc. mg/mL);21.21(Max Conc. mM) DMF:PBS (pH 7.2) (1:5):0.16(Max Conc. mg/mL);0.34(Max Conc. mM) Ethanol:33.33(Max Conc. mg/mL);70.68(Max Conc. mM) |
| form | A solid |
| pka | 15.35±0.40(Predicted) |
| NCI Dictionary of Cancer Terms | zanubrutinib |
| FDA UNII | AG9MHG098Z |
| NCI Drug Dictionary | zanubrutinib |
| ATC code | L01EL03 |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Warning | |||||||||
| Hazard statements | H302-H315-H319-H335 | |||||||||
| Precautionary statements | P261-P305+P351+P338 | |||||||||
| NFPA 704 |
|
Zanubrutinib price More Price(21)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Cayman Chemical | 28924 | Zanubrutinib | 1691249-45-2 | 1mg | $62 | 2024-03-01 | Buy |
| Cayman Chemical | 28924 | Zanubrutinib | 1691249-45-2 | 25mg | $965 | 2024-03-01 | Buy |
| Cayman Chemical | 28924 | Zanubrutinib | 1691249-45-2 | 5mg | $239 | 2024-03-01 | Buy |
| Cayman Chemical | 28924 | Zanubrutinib | 1691249-45-2 | 10mg | $448 | 2024-03-01 | Buy |
| AK Scientific | 3222EM | Zanubrutinib | 1691249-45-2 | 10mg | $273 | 2021-12-16 | Buy |
Zanubrutinib Chemical Properties,Uses,Production
Binding Mode
The electron density map corresponding to zanubrutinib and Cys481 showed covalent linkage with Cys481. Zanubrutinib forms three critical hydrogen bonds with hinge residues Glu475 and Met477. Compared with the co-crystal structure of ibrutinib with BTK, there is an additional hydrogen bond between the backbone carbonyl oxygen of Met477 and the 4-NH. The terminal phenyl group engages in a T-shape π–π stacking with Phe540, and the pyrazolyl nitrogen interacts with Lys430 via a water bridge. The warhead carbonyl also interacts indirectly with the amide NH of Asn484 via two water molecules. Both zanubrutinib and ibrutinib have a piperidinyl linker; however, they adopt two different binding modes in complex with BTK. In addition, a single crystal X-ray structure of zanubrutinib showed a classic intramolecular H-bond between carboxamide oxygen and the 4-NH, which confirmed the bioisosteric mimicry of the aminopyrimidine ring.
Description
Zanubrutinib, a second-generation BTK inhibitor discovered and developed by BeiGene in China, has been approved by the FDA (in 2019) for treating chronic lymphocytic leukemia (CLL) and certain other indications. Zanubrutinib has lower toxicity and better efficacy than ibrutinib. It is in direct competition with AstraZeneca’s acalabrutinib for the $12 billion blood cancer market currently dominated by the first-in-class BTK inhibitor ibrutinib.
Uses
Zanubrutinib is classified as a Bruton''s tyrosine kinase inhibitor. Zanubrutinib is a medication for the treatment of adults with mantle cell lymphoma.
brand name
BrukinsaTM
General Description
Class: non-receptor tyrosine kinase
Treatment: MCL, MZL, WM
Oral bioavailability = 15%
Elimination half-life = 3.3 h
Protein binding = 94%
target
BTK
Metabolism
Zanubrutinib showed a mean terminal elimination half-life of approximately 2–4 h (160 or 320 mg, QD) and an estimated oral bioavailability of 15%, relative to 3.9% (fasting state) for ibrutinib. Zanubrutinib is primarily eliminated hepatically via CYP3A4, but its metabolites have not been characterized.
Zanubrutinib Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| ATK CHEMICAL COMPANY LIMITED | +undefined-21-51877795 | ivan@atkchemical.com | China | 32686 | 60 |
| Shenzhen Nexconn Pharmatechs Ltd | +86-755-89396905 +86-15013857715 | admin@nexconn.com | China | 10247 | 58 |
| BOC Sciences | +1-631-485-4226 | inquiry@bocsci.com | United States | 19553 | 58 |
| HANGZHOU CLAP TECHNOLOGY CO.,LTD | 86-571-88216897,88216896 13588875226 | sales@hzclap.com | CHINA | 6313 | 58 |
| Chemsigma International Co., Ltd. | +86-18136843612 +86-19951791336 | info@chemsigma.com | China | 1095 | 58 |
| Hangzhou Cherry Pharmaceutical Technology Co.,ltd | 0571-81636070 | info@cherrypharmatech.com | CHINA | 274 | 58 |
| Zhejiang J&C Biological Technology Co.,Limited | +1-2135480471 +1-2135480471 | sales@sarms4muscle.com | China | 10523 | 58 |
| Henan Alfa Chemical Co., Ltd | +8618339805032 | alfa4@alfachem.cn | China | 12975 | 58 |
| InvivoChem | +1-708-310-1919 +1-13798911105 | sales@invivochem.cn | United States | 6393 | 58 |
| Beijing Mesochem Technology Co.,Ltd | +8613651027935 | rachel@mesochem.com | China | 191 | 58 |
Related articles
- How to synthesize Zanubrutinib?
- Zanubrutinib is a drug that was shown to effectively treat cancer of B cells without causing severe excessive side effects.
- Jan 25，2024
1691249-45-2(Zanubrutinib)Related Search:
1of4